Abstract
Equecabtagene autoleucel (Fucaso®), an autologous anti-B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy that uses lentivirus as a gene vector to transfect autologous T cells, is being developed by IASO Biotechnology and Innovent Biologics, Inc. for the treatment of multiple myeloma (MM) and autoimmune diseases of the nervous system, including neuromyelitis optica spectrum disorder (NMOSD). Equecabtagene autoleucel was granted conditional approval in China in June 2023 for the treatment of adults with relapsed or refractory MM (RRMM) who have progressed after ≥ 3 lines of therapy (≥ 1 proteasome inhibitor and an immunomodulator). This article summarizes the milestones in the development of equecabtagene autoleucel leading to this first approval in patients with RRMM who have progressed after multiple lines of therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Solimando AG, Krebs M, Desantis V, et al. Breaking through multiple myeloma: a paradigm for a comprehensive tumor ecosystem targeting. Biomedicines. 2023;11(7):2087.
Wang D, Wang J, Hu G, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Blood. 2021;137(21):2890–901.
Xu J, Melenhorst JJ. CT103A, a forward step in multiple myeloma immunotherapies. Blood Sci. 2021;3(2):59–61.
Xie B, Li Z, Zhou J, et al. Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies. Cancers (Basel). 2022;14:3230.
Biotherapeutics IASO. Equecabtagene autoleucel: Chinese prescribing information. Nanjing: IASO Biotherapeutics; 2023.
IASO Biotherapeutics. IASO Bio and Innovent announce the NMPA approval of the new drug application for equecabtagene autoleucel, the world's first fully-human BCMA CAR-T therapy, for the treatment of relapsed and/or refractory multiple myeloma [media release]. 3 Jul 2023. https://www.iasobio.com/.
Innovent Biologics Inc., IASO Biotechnology. Innovent and IASO Bio announce the NMPA approval of FUCASO®, the first fully-human BCMA CAR-T therapy, for the treatment of relapsed or refractory multiple myeloma [media release]. 3 Jul 2023. https://www.innoventbio.com/.
National Medical Products Administration. The National Medical Products Administration conditionally approved the marketing of equecabtagene autoleucel injection. 2023. https://www.nmpa.gov.cn/yaowen/ypjgyw/20230630195006116.html?type=pc&m. Accessed 8 Aug 2023.
Qin C, Tian DS, Zhou LQ, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023;8(1):5.
Sana Biotechnology. Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics announce non-exclusive license agreement for clinically validated BCMA CAR construct [media release]. 10 Jan 2022. https://www.sana.com.
Li C, Wang D, Song Y, et al. Updated phase 1/2 data of safety and efficacy of CT103A, fully human BCMA-directed CAR T cells, in relapsed/refractory multiple myeloma [abstract no. S187]. HemaSphere. 2022;6(S3):182–3.
Li C, Wang D, Song Y, et al. CT103A, a novel fully human BCMA-targeting CAR-T cells, in patients with relapsed/refractory multiple myeloma: updated results of phase 1b/2 study (FUMANBA-1) [abstract plus poster]. J Clin Oncol. 2023;41(16 Suppl):8025.
Mu W, Long X, Cai H, et al. A model perspective explanation of the long-term sustainability of a fully human BCMA-targeting CAR (CT103A) T-cell immunotherapy. Front Pharmacol. 2022;13: 803693.
Li CR, Wang D, Fang BJ, et al. Updated results of Fumanba-1: a phase 1b/2 study of a novel fully human B-cell maturation antigen-specific CAR T cells (CT103A) in patients with relapsed and/or refractory multiple myeloma [abstract no. 704]. Blood. 2022;140(Suppl 1):7435–6.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability
Not applicable.
Additional information
This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Keam, S.J. Equecabtagene Autoleucel: First Approval. Mol Diagn Ther 27, 781–787 (2023). https://doi.org/10.1007/s40291-023-00673-y
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40291-023-00673-y